Wednesday, May 18, 2022 4:26:40 PM
That was after I offered all the calculations and sources.
So if you are going to say something like that, prove it with facts, sources and calculations.
Now you are saying something different. That we don't know. But let's recapitulate, what I said is that all of the patients with KNOWN MGMT gene promoter methylation status in the group of these 35 patients that never crossed over are MGMT methylated and that of the patients with still unknown MGMT gene promoter methylation status, almost all if not all are MGMT Methylated.
This last part is the only one that you could have seen as speculation. But actually it wasn't. If you apply simple statistics, you have a group of 35 patients with the following distribution:
- Known MGMT 13
- Unknown MGMT 22
Out of the 13 with known MGMT methylation you have:
- Methylated 13 100%
- Non Methylated 0 0%
Do you know how big is this sample from a statistical point of view to infer something from it? Hard to find a sample as big as this 37% (13/35) in a survey. We know the information for 37% of the universe to make a statistical analysis and in that sample, 100% of them are Methylated.
Finally, I have always believed what you mention here:
And actually I used that as a support in the statistical analysis I did, because this means that the selection of the population of patients with unknown MGMT is not biased towards unmethylated, nor methylated MGMT because the trial was randomized at the beginning and the MGMT Methylated and MGMT Unmethylated patients were assigned to both original arms in the statistically correct proportions.
So, I say that at least the majority of the 35 non crossed over patients are MGMT Methylated and this is not speculation, is a conclusion statistically inferred. Also, the rest of my post definitely was not speculation, was made up of facts, calculations and analyses.
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM